Accipiter Biosciences
Accipiter Biosciences uses computational protein design to develop de novo protein therapies that engage multiple cell-surface receptors and pathways in one stable molecule. Its therapies are designed for complex diseases, including autoimmune disorders and cancer, as an alternative to combination treatments.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2023 Seattle business license
- Type
- Corporation Seattle business license
- Employees
- 26
- Registered name
- Accipiter Biosciences Inc Seattle business license
- Stage
- Seed
- Members see funding amounts. .
Is this your organization? Claim it
Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline
Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.
Seattle’s Accipiter Bio Raises $12.7M, Partners with Pfizer and Kite Pharma to Advance AI-Designed Multi-Target Protein Therapies
Seattle biotech startup Accipiter Biosciences, founded by researchers from Nobel laureate David Baker's lab, secured $12.7 million and partnerships with Pfizer and Kite Pharma to develop AI-designed multi-target proteins aiming to improve disease treatment efficacy and reduce clinical trial costs.
By Accipiter Biosciences
Accipiter Biosciences raises $12.7M seed from Takeda and Flying Fish Partners to advance de novo protein therapeutics
Accipiter Biosciences announced a $12.7 million seed round led by Takeda and Flying Fish Partners to fund its de novo protein therapeutics platform and advance preclinical immunology and oncology programs, with strategic collaborations already in place with Pfizer and Kite Pharma.
People
See all 4-
Matthew Bick co-founder and Chief Executive Officer
-
Hector Rincon-Arano Co-founder and Chief Scientific Officer
-
Javier Castellanos Co-founder and Chief Technology Officer
Online
Questions about Accipiter Biosciences
What is Accipiter Biosciences?
Accipiter Biosciences is a startup based in Seattle, Washington, US that uses computational protein design to develop de novo protein therapies. Its therapies target multiple cell-surface receptors and pathways in one stable molecule for complex diseases, including autoimmune disorders and cancer.
What has Accipiter Biosciences been in the news for?
GeekWire reported in July 2026 that Accipiter Biosciences was accelerating AI-designed multi-target protein drugs and expanding its clinical pipeline. In November 2025, GeekWire reported that Accipiter Biosciences partnered with Pfizer and Kite Pharma to advance AI-designed multi-target protein therapies.
Who are the people behind Accipiter Biosciences?
Accipiter Biosciences' co-founders are Matthew Bick, chief executive officer; Hector Rincon-Arano, chief scientific officer; and Javier Castellanos, chief technology officer. William Canestaro is an executive, chief strategy officer and chief operations officer.
Who invested in Accipiter Biosciences, and how much has it raised?
Members of Seattle Flow see Accipiter Biosciences' funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Accipiter Biosciences based?
Accipiter Biosciences is based in Seattle, Washington, US.
When was Accipiter Biosciences founded?
Accipiter Biosciences was founded in 2023.